+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a combination therapy of ruxolitinib, steroids, and lenalidomide in adults with relapsed or refractory multiple myeloma MM who have progressive disease despite previous treatments. MM is a cancer of plasma cells in the bone marrow with complex causes and limited curative options. This phase 1, open-label, multicenter study aims to assess the safety and effectiveness of these drugs together in patients who have failed at least two prior therapies including immunomodulatory drugs and proteasome inhibitors. Participants receive varying doses of ruxolitinib orally twice daily, lenalidomide once daily, and methylprednisolone every other day. The study includes dose escalation periods and treatment adjustments based on disease progression. Some groups start with ruxolitinib and steroids, adding lenalidomide only if the disease worsens. Treatment continues until disease progression or unacceptable side effects occur. During the study, participants will have regular evaluations including blood tests and clinical assessments to monitor safety, side effects, and treatment response. Researchers will measure outcomes such as the maximum tolerated dose, adverse events, response rates, progression-free and overall survival over a follow-up period extending up to 54 months. Participants are expected to adhere to visit schedules and study requirements throughout the trial.

Age: 18Years +All GendersPhase 1
13 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are conducting an observational registry to collect standardized data from adult patients receiving routine oncology care at participating cancer centers. The study aims to gather detailed information such as baseline patient characteristics, treatments administered, and outcomes to support research and improve clinical trial participation. Patient surveys are also included to enrich the data collected. No treatments or interventions are given as part of this registry. Instead, data is gathered from patients receiving their usual cancer care. This open-ended registry will continuously collect and analyze information over time to better understand treatment patterns, safety, and effectiveness. Participants will provide informed consent and contribute data through their regular care visits and surveys. Researchers will monitor treatment effectiveness mainly by tracking the time until treatment discontinuation. The registry will regularly analyze and present the data collected. Participation may last as long as the patient is receiving treatment and contributing data, with long-term follow-up possible.

Age: 18Years - 120YearsAll Genders
7 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.

Age: 18Years +All GendersPhase 3
283 locations
P

Actively Recruiting

Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.

Age: 18Years +All Genders
11 locations
S

Actively Recruiting

Researchers are comparing two approaches to supportive cancer care for adults with cancer. This trial aims to evaluate which method better improves health-related quality of life, patient activation, satisfaction with care and decision-making, documentation of goals and symptoms, and reduces acute care use such as emergency visits and hospitalizations. The study focuses on patients with newly diagnosed or recurrent solid tumor cancers. Participants are assigned to one of two groups. One group receives educational materials about advance care planning and symptom management through technology messages weekly for the first 4 months and biweekly for months 5 through 12. The other group works with a lay health worker who discusses the same materials in person or by phone on the same schedule over 12 months. Both groups receive ongoing supportive care tailored to improve their cancer experience. Participants complete a baseline interview at enrollment by phone, followed by surveys at 3, 6, and 12 months. Researchers track changes in quality of life using the FACT-G questionnaire, patient activation, satisfaction with care and decision-making, use of palliative and hospice care, emergency visits, hospitalizations, and documentation of care goals and symptoms. The study runs through February 2028, allowing long-term monitoring of supportive care outcomes.

Age: 18Years +All GendersPhase Not Applicable
17 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Researchers are evaluating how tailored telehealth psychotherapy environments affect clinical outcomes for children with mood and anxiety disorders. This Phase II randomized trial compares Teleo, a virtual therapy platform designed specifically for youth psychotherapy, to standard video conferencing platforms like Zoom. The study will assess patient engagement and various clinical metrics including treatment duration, medication needs, and symptoms of anxiety and depression. Participants will be randomly assigned to receive 12 sessions of therapist-led psychotherapy either through the Teleo platform or standard video conferencing methods. Sessions will be recorded, and clinical data along with questionnaires will be collected. The trial will monitor cancellation and no-show rates, clinician satisfaction, and treatment dropout over a 12-week period. Families involved in the study will complete assessments such as the Child Involvement Rating Scale during the first week and repeated measures of anxiety, depression, and therapy perceptions at multiple points. Researchers will also track long-term care costs one year after enrollment. Participation includes regular therapy sessions and questionnaire completion, with ongoing evaluation of both clinical and engagement outcomes until the study ends in 2027.

Age: 5Years - 14YearsAll GendersPhase Not Applicable
2 locations
P

Actively Recruiting

Researchers are building a prospective group of patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have common EGFR mutations, specifically EGFR exon 19del or exon 21 L858R. The study focuses on patients diagnosed on or after January 1, 2024, and aims to collect standardized data at key points before treatment starts, during treatment, and when treatment ends. The main goal is to observe real-world progression-free survival among those treated with first-line osimertinib. Participants may receive osimertinib combined with chemotherapy or other treatment regimens initiated after January 1, 2024, or osimertinib alone as monotherapy for newly diagnosed metastatic NSCLC. About 30% of patients enrolling before starting osimertinib will have imaging done at set intervals to monitor disease progression. Treatments are given as part of routine clinical care without experimental procedures. Throughout the study, data will be collected at baseline, during treatment, and at therapy discontinuation. Researchers will assess progression-free survival, overall survival, and time to stopping treatment, tracking these outcomes up to 100 months from treatment start. Participants are observed in a real-world setting, with no investigational drugs administered, and the study will continue until April 2029.

Age: 18Years +All Genders
10 locations